Conventional identification of EGFR mutations requires biopsy and genetic testing which has several limitations in clinical practice: (1) the potential risk of tumor metastasis during biopsy; (2) the difficulty in obtaining representative tumor tissue due to tumor genetic heterogeneity; (3) not all tumors of all sizes and locations are suitable for biopsy; (4) a lack of adequate material and high-quality DNA may lead to testing failure; (5) genetic mutations may change throughout treatment, while repeated biopsies are impractical. Here, EGFR is linked to neoplasm.